Rchr
J-GLOBAL ID:201801006753532435
Update date: Sep. 10, 2024
Suzuki Susumu
スズキ スズム | Suzuki Susumu
Affiliation and department:
Other affiliations (1):
Research field (2):
Tumor biology
, Tumor diagnostics and therapeutics
Research keywords (5):
Immunotherapy
, Immune checkpoint
, Cytotoxic T-lymphocyte
, regulatory T-cells
, Tumor immunology
Research theme for competitive and other funds (17):
- 2024 - 2027 がん局所におけるTreg免疫抑制機序に基づく新たなTreg標的がん免疫療法の開発
- 2022 - 2027 制御性T細胞の機能に着目した進行腎癌一次治療の選択に有用なバイオマーカーの 探索
- 2024 - 2025 和漢薬のがん免疫療法に対する補強効果
- 2021 - 2024 Development of novel cancer immunotheray by combining regulatory T-cell elimination and TGF-b inhibitors
- 2021 - 2024 頸部リンパ節における腫瘍免疫環境の解明-免疫学的頸部郭清術の確立を目指して
- 2019 - 2022 1. ゲノム編集によるFLT3変異改変ヒト白血病細胞の作製と新規治療法の探索
- 2018 - 2021 がん免疫抑制環境の改善に基づく新たながん免疫療法の開発に向けた基礎的研究
- 2017 - 2020 頭頸部がん治療における新たなる免疫化学療法の開発- CTLと抗がん薬併用の意義
- 2017 - 2020 子宮頸がんを発生させるHPVのE7蛋白を標的とした細胞内分子標的療法の開発
- 2016 - 2018 がん免疫療法における抗CCR4抗体によるTreg除去療法
- 2014 - 2017 エフェクター制御性T細胞の統合的制御に基づく新たながん免疫治療法の確立
- 2012 - 2016 Combination therapy using cancer vaccine, antigen-specific CTL and an anticancer drug for renal cell carcinoma
- 2010 - 2013 低フコシル化抗体を用いた包括的がん免疫療法の開発
- 2012 - 2012 抗原特異的CTL調製法の確立と臨床応用
- 2009 - 2010 抗原特異的細胞傷害性T細胞(CTL)の閉鎖調製キットの開発とその臨床応用
- 2006 - 2007 抗原特異的CTLのGMP対応体外閉鎖無菌培養システム開発
- 2001 - 2001 プロテインマイクロアレイによる造血器腫瘍の新規診断技術の開発
Show all
Papers (60):
-
Aya Yamamura, Moe Fujiwara, Akiko Kawade, Taiki Amano, Alamgir Hossain, Md Junayed Nayeem, Rubii Kondo, Yoshiaki Suzuki, Yasumichi Inoue, Hidetoshi Hayashi, et al. Corosolic acid attenuates platelet-derived growth factor signaling in macrophages and smooth muscle cells of pulmonary arterial hypertension. European journal of pharmacology. 2024. 973. 176564-176564
-
Susumu Suzuki, Toyonori Tsuzuki, Masato Saito, Toshihiko Ishii, Taishi Takahara, Akira Satou, Daisuke Inukai, Shunpei Yamanaka, Kazuhiro Yoshikawa, Ryuzo Ueda, et al. Regulatory T-cells activated in metastatic draining lymph nodes possibly suppress cancer immunity in cancer tissues of head and neck squamous cell cancer. Pathology international. 2024
-
Hiroki Okamoto, Kazuhiro Yoshikawa, Akiko Shimada, Rui Sano, Daisuke Inukai, Shunpei Yamanaka, Susumu Suzuki, Ryuzo Ueda, Hiromi Ueda, Yasushi Fujimoto, et al. Artesunate and cisplatin synergistically inhibit HNSCC cell growth and promote apoptosis with artesunate-induced decreases in Rb and phosphorylated Rb levels. Oncology reports. 2023. 50. 2
-
Hiromu Nakamura, Tetsuya Ogawa, Shunpei Yamanaka, Daisuke Inukai, Takashi Maruo, Taishi Takahara, Akira Satou, Toyonori Tsuzuki, Susumu Suzuki, Ryuzo Ueda, et al. Immune Status of Cervical Lymph Nodes in Head and Neck Cancer-A Surgical Oncology Perspective. Journal of personalized medicine. 2023. 13. 7
-
Shunpei Yamanaka, Susumu Suzuki, Hideaki Ito, Karnan Sivasundaram, Ichiro Hanamura, Ikuko Okubo, Kazuhiro Yoshikawa, Shoya Ono, Taishi Takahara, Akira Satou, et al. Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens. International journal of molecular sciences. 2023. 24. 2
more...
MISC (34):
-
加藤 康孝, 鈴木 進, 大久保 井久子, 山中 俊平, 犬飼 大輔, 中村 宏舞, 小川 徹也, 村上 五月, 花村 一朗, 高見 昭良, et al. 抗癌剤療法を受けている肺癌患者に対する3回目のSARS-CoV-2ワクチン接種の効果(The effect of third SARS-CoV-2 vaccination on lung cancer patients receiving anticancer drug therapy). 日本癌学会総会記事. 2023. 82回. 1392-1392
-
鈴木 進, 花村 一朗, 村上 五月, 風岡 宣暁, 高見 昭良. HLA拘束性細胞傷害活性モデルの確立と,がん免疫治療併用薬探索への応用. MHC: Major Histocompatibility Complex. 2023. 30. 2. 119-119
-
Yutaro Kondo, Taishi Takahara, Shoya Ono, Mitsuo Goto, Tetsuya Ogawa, Hideaki Ito, Akira Sato, Toyonori Tsuzuki, Kazuhiro Yoshikawa, Ryuzo Ueda, et al. Transforming growth factor-beta inhibitor is a candidate drug for immunotherapy of oral squamous cell carcinoma. CANCER SCIENCE. 2022. 113
-
Shunpei Yamanaka, Susumu Suzuki, Hideaki Ito, Shoya Ono, Yutaro Kondo, Daisuke Inukai, Hiroki Okamoto, Taishi Takahara, Toyonori Tsuzuki, Kazuhiro Yoshikawa, et al. Establishment passive culture cells derived from mucoepidermoid carcinoma. CANCER SCIENCE. 2022. 113. 1743-1743
-
Yutaro Kondo, Susumu Suzuki, Mitsuo Goto, Shoya Ono, Tetsuya Ogawa, Kazuhiro Yoshikawa, Toyonori Tsuzuki, Ryuzo Ueda. PD-L1 expression mechanisms are heterogeneous in oral cancer. CANCER SCIENCE. 2021. 112. 863-863
more...
Patents (5):
-
エフェクター制御性T細胞の検出及び調製
-
KIT FOR PREPARATION OF ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTE
-
METHOD FOR PRODUCING VIRUS-SPECIFIC CTL
-
CYTOTOXIC T-CELL EPITOPE PEPTIDE AND USE THEREOF Applicants
-
METHOD OF ASSYAING PHOSPHORYLATION ENZYME ACTIVITY OF CYCLIN/CDK COMPLEX
Books (12):
-
Tregを標的としたがん免疫治療. 特集;免疫療法の進歩と問題点
腫瘍内科, 20(2):137-142 2017
-
モガムリズマブの新しい展開
最新医学 2016年 71巻 1号 126-32 2016
-
抗腫瘍抗体 - がん細胞に対する抗体の現状と展望 実験医学 増刊 がん免疫療法 腫瘍免疫学の最新知見から治療法のアップデートまで
実験医学 Vol.34 No.12 2016 122-131 2016
-
成人T細胞白血病/リンパ腫におけるトリプトファン代謝の予後に関する意義
臨床血液2015年56巻 11号 2295-304 2015
-
Progress in clinical use of CCR4 antibody for regulatory T cell suppression. Inflammation and Immunity in Cancer
Springer 2015
more...
Lectures and oral presentations (63):
-
The effect of third SARS-CoV-2 vaccination on lung cancer receiving maintenance anticancer therapy.
(2023)
-
HLA 拘束性細胞傷害活性モデルの確立と、がん免疫治療併用薬探索への応用
(第6回東海北陸HLA研究会 2023)
-
T-cell receptor repertoire similarity in regulatory T-cells between draining lymph nodes and cancer tissues.
(2nd JCA-AACR Precision Cancer Medicine International Conference. 2023)
-
Trametinib improves Treg selectivity of α-CCR4 mAb by regulating CCR4 xpression in CTLs induced via TCR/TGF-β signaling
(第81回日本癌学会学術総会 2022)
-
Establishment of passive culture cells derived from mucoepidermoid carcinoma
(第80回日本癌学会学術総会 2021)
more...
Education (2):
- 1993 - 2001 Nagoya University School of Medicine
- 1980 - 1984 Meijo University Faculty of Agriculture
Professional career (1):
Work history (8):
Committee career (1):
Association Membership(s) (1):
THE JAPANESE CANCER ASSOCIATION
Return to Previous Page